


## SL-23. Oncology Phenotypic Screening. Colon Cancer

Phenotypic screening is a firmly established technology that has contributed to the identification of valuable therapeutic agents for oncology drug discovery [1]. More specifically, in colon cancers multiple etiological pathways are responsible for disease onset and development [2].

At ASINEX we have evaluated the susceptibility of several colon cancer cell lines (HCT-116, SW-620, COLO-320,

RKO) to a diverse array of small molecules and identified a series of related compounds that kill cancer cells at sub- $\mu\text{M}$  concentrations with limited off target effect on healthy cells (human fibroblasts). Additional screening in a cell-based luciferase reporter assay of Wnt signaling has provided preliminary evidence of Wnt-dependent mechanism of action.

**Signature Library 23**

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 $\mu\text{mol}$ ; 1 $\mu\text{mol}$ DMSO solutions	EC <sub>50</sub> MTT test Solubility data in PBS SL#23_MTT_06-16.sdf

**References:**

1. *Nature Reviews Drug Discovery* 13, 588–602 (2014) doi:10.1038/nrd4366.
2. *Gastroenterol Rep (Oxf)*. 2015 Nov; 3(4): 269–276 doi:10.1093/gastro/gov046

**Contact us:**

USA: +1 336 721 1617  
Japan: +81-80-3401-9097  
Europe/Global:

[mparisi@asinex.com](mailto:mparisi@asinex.com)  
[sota@asinex.com](mailto:sota@asinex.com)  
[lsadovenko@asinex.com](mailto:lsadovenko@asinex.com)